CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

R. C. Prins; R. T. Burke; J. W. Tyner; B. J. Druker; M. M. Loriaux; S. E. Spurgeon

doi:10.1038/leu.2013.228

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

R. C. Prins, R. T. Burke, J. W. Tyner, B. J. Druker, M. M. Loriaux, S. E. Spurgeon

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2094-2096
Number of pages	3
Journal	Leukemia
Volume	27
Issue number	10
DOIs	https://doi.org/10.1038/leu.2013.228
State	Published - Oct 2013

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2013.228

Cite this

Prins, R. C., Burke, R. T., Tyner, J. W., Druker, B. J., Loriaux, M. M., & Spurgeon, S. E. (2013). CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia, 27(10), 2094-2096. https://doi.org/10.1038/leu.2013.228

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. / Prins, R. C.; Burke, R. T.; Tyner, J. W. et al.
In: Leukemia, Vol. 27, No. 10, 10.2013, p. 2094-2096.

Research output: Contribution to journal › Letter › peer-review

Prins, RC, Burke, RT, Tyner, JW , Druker, BJ , Loriaux, MM & Spurgeon, SE 2013, 'CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway', Leukemia, vol. 27, no. 10, pp. 2094-2096. https://doi.org/10.1038/leu.2013.228

Prins RC, Burke RT, Tyner JW , Druker BJ , Loriaux MM , Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-2096. doi: 10.1038/leu.2013.228

@article{666eafa0954746c2b1d6d02317377a88,

title = "CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway",

author = "Prins, {R. C.} and Burke, {R. T.} and Tyner, {J. W.} and Druker, {B. J.} and Loriaux, {M. M.} and Spurgeon, {S. E.}",

year = "2013",

month = oct,

doi = "10.1038/leu.2013.228",

language = "English (US)",

volume = "27",

pages = "2094--2096",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

AU - Prins, R. C.

AU - Burke, R. T.

AU - Tyner, J. W.

AU - Druker, B. J.

AU - Loriaux, M. M.

AU - Spurgeon, S. E.

PY - 2013/10

Y1 - 2013/10

UR - http://www.scopus.com/inward/record.url?scp=84885658308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885658308&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.228

DO - 10.1038/leu.2013.228

M3 - Letter

C2 - 23900138

AN - SCOPUS:84885658308

SN - 0887-6924

VL - 27

SP - 2094

EP - 2096

JO - Leukemia

JF - Leukemia

IS - 10

ER -

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this